AI-Generated Summary

US President Donald Trump's proposed 100% tariff on branded and patented pharmaceutical imports, set for October 2025, is unlikely to immediately affect Indian exports, according to industry experts. The tariff specifically excludes generic medicines, which constitute the majority of India's pharmaceutical exports to the US, and many Indian companies already have US manufacturing presence. India is a critical supplier of generics and biosimilars to the US, accounting for nearly 47% of its pharmaceutical requirements.

In a nutshell

This analysis provides crucial foresight for pharmaceutical executives, investors, and policymakers regarding potential shifts in global pharmaceutical trade policy. It highlights the resilience of the Indian generic drug market and prompts strategic considerations for future policy changes and diversification into complex generics and biosimilars.

Source: Lokmat Times